ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Reglan & Tardive Dyskinesia

Marketed by ANI Pharmaceuticals, Reglan is prescribed for a number of gastrointestinal problems. The drug comes with the risk of several serious side effects, including tardive dyskinesia, a condition involving involuntary facial and body movements. In 2011, Reglan was estimated to be used by more than 2 million Americans.

Reglan (metoclopramide) is a prescription medication manufactured by Minnesota-based drugmaker ANI Pharmaceuticals Inc. and is part of a class of drugs called antiemetics. An antiemetic is a drug that is used to treat vomiting and nausea, conditions that can cause vomiting and nausea, or vomiting and nausea caused by certain drug treatments, such as chemotherapy or general anesthetics.

Reglan was approved by the U.S. Food and Drug Administration (FDA) in 1979, and has been available on the U.S. market as a prescription drug ever since. It is available in orally disintegrating tablets or injections. However, the brand-name oral solution is no longer available. The generic version of Reglan, named after its active ingredient metoclopramide and made by several different manufacturers, is available in both tablet form and oral solution.

Treatment with Reglan may result in adverse reactions including a very serious condition called tardive dyskinesia (TD). TD is a disorder affecting certain muscles in the body, resulting in involuntary, repetitive body movements that may include grimacing, sticking out the tongue or smacking the lips.

Reglan’s association to the development of TD, especially with long-term use, necessitated the inclusion of a boxed warning, also called a black box warning, to the drug’s label in 2009. A black box warning is the FDA’s most serious type of warning and is used to call attention to serious or life-threatening risks linked to prescription drug-use.

What Does Reglan Treat?

Reglan treats conditions affecting the gastrointestinal tract including gastroesophageal reflux (also commonly called GERD) and diabetic gastroparesis. Reglan is prescribed for short-term use in patients with GERD who fail to respond to more conventional therapies. The drug can also provide relief of symptoms to patients with acute (sudden and severe) and recurrent (occurring often or repeatedly) diabetic gastroparesis, a condition that occurs when the stomach takes too long to empty food.

Reglan has also been found to be effective in treating other conditions involving nausea and vomiting as well as nausea and vomiting associated with the use of certain medications.

Reglan treats:
  • Slow stomach emptying in people with diabetes, also known as gastroparesis
  • Nausea and vomiting that can happen with cancer chemotherapy
  • Nausea and vomiting that may happen after surgery in patients whose doctors do not want them treated with a stomach tube and suction

What Is Gastroparesis?

Gastroparesis is a chronic condition that reduces the stomach’s ability to empty its contents normally. It does not involve a blockage, or stomach or gastrointestinal obstruction, of any kind.

The disorder is sometimes associated with diabetes, a disease in which a patient’s blood glucose (sugar) levels are too high. It can also occur after some surgeries. However, the exact cause of gastroparesis is unknown, but it may be the result of a disruption of nerve signals to the stomach, according to the National Institutes of Health (NIH). Certain medicines may work to block these nerve, signals causing the complication to occur.

It is estimated that approximately 5 million people in the United States are affected by gastroparesis.

Symptoms of the condition include:
  • Nausea
  • Vomiting
  • Bloating (abdominal distention or premature abdominal fullness after meals)
  • Abdominal pain
  • Heartburn
  • Anorexia (eating disorder characterized by self-starvation and excessive weight loss)
  • Weight loss without trying
  • Hypoglycemia (abnormally low levels of blood sugar) in patients with diabetes

Possible serious complications of gastroparesis can result from ongoing nausea and vomiting or poor blood sugar control in people with diabetes.

These complications can include:
  • Dehydration
  • Electrolyte imbalances
  • Malnutrition
  • Diabetes complications

What is GERD?

Gastroesophageal reflux disease, or GERD, is a condition in which the stomach’s contents leak backwards from the stomach into the esophagus. The esophagus is the “tube” that spans from the mouth to the stomach. When food and stomach acids back up into this tube, it becomes irritated and/or damaged, causing heartburn and other symptoms.

image of stomach acid entering the esophagus
When food and stomach acids back up into the esophagus, it may lead to heartburn and other symptoms

Heartburn is also called acid indigestion. It is a burning sensation in the central part of the chest or upper central abdomen. The pain can also be felt in the neck, throat or jaw area. Other symptoms of GERD might include a feeling that food is stuck behind the breastbone, or nausea after eating.

Less common symptoms of the condition include:
  • Bringing food back up (regurgitation)
  • Coughing or wheezing (high-pitched whistling sound made when a person breathes)
  • Difficulty swallowing
  • Hiccups
  • Hoarseness or voice changes
  • Sore throat

Symptoms may be worse at night, or when a person bends over or lays down, or after eating.

Complications of GERD can include:
  • Worsening of asthma
  • Change in the lining of the esophagus that can increase a patient’s cancer risk (Barrett esophagus)
  • Bronchospasm (irritation and spasm of the airways caused by acid)
  • Chronic (long-term) cough or hoarseness
  • Dental problems due to acid
  • Ulcers in the esophagus
  • Stricture, or narrowing of the esophagus due to scarring

How Does Reglan Work?

Reglan works in the digestive tract in different ways. For gastroparesis, Reglan works by affecting different receptors in the gastrointestinal (GI) tract, including a dopamine receptor that has a relaxant effect on the gut. Overall, the drug facilitates increased gastric emptying by enhancing contractions in the stomach and small intestine and decreasing relaxation in part of the stomach after meals.

Illustration of the GI tract
Reglan affects different receptors in the GI tract in order to facilitate gastric emptying

Although Reglan works in most of the GI tract, it has little to no effect on the colon. The drug does, however, increase the tightness of the esophageal sphincter (or muscular ring that closes the esophagus when food is not being swallowed), which prevents the contents of the stomach from coming back up into the esophagus (GERD).

It can also act to relieve nausea and vomiting by blocking dopamine receptors in the brain. Dopamine is a neurotransmitter, or chemical messenger, in the brain that controls the reward and pleasure centers. Thereby, dopamine receptors are able to activate the part of the brain that controls nausea and vomiting. By blocking those receptors, patients may be alleviated of symptoms.

Reglan Side Effects

In approximately 10 percent of patients given 10 mg of Reglan (metoclopramide) four times daily, the most commonly reported side effects included restlessness, drowsiness, fatigue and lassitude (mental weariness or lack of energy). The incidence of such adverse reactions was dependent upon dosage and duration of drug exposure.

Some adverse reactions occurred after Reglan treatment was discontinued, especially involving the nervous system. These side effects included dizziness, nervousness and headaches.

Use of Reglan, especially for longer than 12 weeks, carries the risk of developing a condition known as tardive dyskinesia (TD), a neurological disorder that involves involuntary, rapid movements of the face and body.

Depending on the person, TD symptoms may be mild and only last for a short time or they may continue indefinitely. If the condition is diagnosed early enough, changing medications may be enough. In some instances, however, it can be permanent.

FDA Requires Black Box Warning for Reglan

According to an FDA study conducted in 2007, a number of patients were prescribed Reglan for long-term use (defined as longer than 3 months) and this increased the number of people who suffered side effects, including TD. The incidence of TD in long-term Reglan users is cited to be as high as 20 percent in the literature. This led to the FDA requiring a black-box warning in 2009. The warning advises patients about the dangers of developing tardive dyskinesia after long-term use of Reglan and its generic counterparts.

Reglan Tardive Dyskinesia Black-Box Label

The FDA recommends avoiding treatment with Reglan for longer than 12 weeks, but rare cases may arise in which the therapeutic benefit of the drug is deemed to outweigh the risk of TD. Its use should be discontinued in patients who develop signs of TD. In some instances, taking the drug can suppress or partially suppress the signs of TD, masking the underlying disease process.

FDA: Tell Your Doctor About Medical Conditions

If you have kidney problems, your doctor may opt to prescribe a lower dose. For patients with liver problems and heart failure, Reglan may cause the body to retain fluids. And in diabetics, patients taking Reglan may have to have their insulin dose adjusted.

According to the FDA, it is not known if Reglan will harm fetuses. It can pass into breast milk and may harm a breast-feeding infant.

Still, according to some reports, nursing mothers have taken drugs, including Reglan, to help them produce more milk, even though doctors say this can be risky. Lactation consultants have prescribed the drugs, saying they can increase the hormone responsible for breast milk production, prolactin.

The FDA recommends telling your doctor about all medical conditions before taking Reglan, including:
  • Depression
  • Parkinson’s Disease
  • High blood pressure
  • Kidney problems
  • Liver problems
  • Heart failure
  • Diabetes
  • Breast cancer
  • Phenylketonuria
  • Pregnancy or planned pregnancy
  • Breast feeding

Reglan Dosages and Administration

Reglan comes in two tablet strengths – 5 milligrams and 10 milligrams. The pills are differentiated by color and shape as well as the pills’ markings (debossed descriptions).

Reglan Pills
5 mg tablet
  • Green
  • Elliptical-shaped (oval shape known as an ellipse)
  • Marked with “REGLAN” over “5” on one side and “ANI” on the opposite side
Reglan 10 mg pills
10 mg tablet
  • White
  • Double-edge scored
  • Capsule-shaped
  • Marked with “REGLAN” on one side and “ANI 10” on the other

Gastroesophageal (Acid) Reflux

Patients being treated for gastroesophageal reflux (also more commonly known as acid reflux) should take the recommended dose of Reglan four times a day, either continuously or intermittently (as needed), or at specific times of the day. The recommended adult dosage of Reglan is 10 to 15 mg taken four times daily for four to 12 weeks. Treatment duration is dependent upon the patient’s response to the medication and improvement of their condition as shown by follow-up endoscopic testing.

Reglan works best for acid reflux if taken 30 minutes before each meal and at bedtime. Patients using Reglan to treat acid reflux should not take more than the maximum recommended daily dosage of 60 mg. If taken intermittently, or only as symptoms occur, a single dose of Reglan up to 20 mg can be administered as the situation warrants.

Acute and Diabetic Gastroparesis

The recommended adult dosage of Reglan for the treatment of sudden and severe diabetic gastroparesis, or gastroparesis that occurs often or repeatedly, is 10 mg taken four times a day for two to eight weeks, depending on a patient’s symptomatic response. Reglan dosages should be taken 30 minutes before each meal and at bedtime. Patients with gastroparesis should not take more than the maximum recommended daily dosage of 40 mg of Reglan.

If patients with diabetic gastroparesis suffer from severe nausea or vomiting and are unable to take Reglan tablets orally, treatment with Reglan can begin by injection. These injections can be given intramuscularly (administered directly into the muscle) or intravenously for up to 10 days. After patients are able to take Reglan orally, treatment should continue with Reglan tablets for no longer than 12 weeks of total treatment time.

Dosage Adjustments and Elderly Patients

Dosage adjustments should be made for patients with the following conditions:
  • Moderate to severe liver impairment
  • Moderate to severe kidney impairment
  • End-stage kidney disease
  • Those who poorly metabolize CYP2D6 (an enzyme primarily associated with the liver)
Dosage adjustments should also be made for those taking strong CYP2D6 inhibitors, such as:
heart medication – helps the heart beat regularly
used to help people quit smoking
selective serotonin reuptake inhibitor – SSRI – used to treat premenstrual dysphoric disorder – PMDD
used to treat depression, anxiety attacks, OCD, panic attacks, PTSD and PMDD

Elderly patients may be more sensitive to the effects of Reglan. A lower starting dosage of 5 mg taken four times a day is recommended. Depending on the patient’s response and tolerability to the drug, the dosage may be gradually increased to the recommended adult dosage of 10 mg taken four times daily.

Reglan Overdose

There is no specific antidote (reversal agent) for Reglan overdose.

Symptoms of Reglan overdose can include:
  • Drowsiness
  • Disorientation
  • Extrapyramidal reactions (drug-induced movement disorders)
  • Other adverse reactions associated with Reglan-use
  • Death

Drug Interactions

Reglan’s effects may be intensified or diminished when used concurrently with other medications. Reglan may also affect the clinical efficacies of certain medications in patients. Using Reglan along with other medications can also lead to an increased risk of certain side effects or unknown adverse reactions. Patients should always inform their doctor of all medications and/or supplements they are currently taking before beginning treatment with Reglan.

Medications that may interact with Reglan include:
  • Insulin
  • Antipsychotics
  • Strong CYP2D6 inhibitors - Quinidine, bupropion, fluoxetine, paroxetine
  • Monoamine oxidase inhibitors (MAOIs)
  • Central nervous system (CNS) depressants - Alcohol, sedatives, hypnotics, opiates, anxiolytics
  • Drugs that impair gastrointestinal motility - Antiperistaltic antidiarrheal drugs, anticholinergic drugs, opiates
  • Dopaminergic agonists and other drugs that increase dopamine concentrations - Apomorphine, bromocriptine, cabergoline, levodopa, pramipexole, ropinirole, rotigotine
  • Succinylcholine, Mivacurium
  • Drugs with absorption altered due to increased gastrointestinal motility - Drugs with decreased absorption include digoxin, atovaquone, posaconazole oral suspension, fosfomycin. Drugs with increased absorption include sirolimus, tacrolimus, cyclosporine.
Reglan Pills
Reglan Facts
  1. Used to Treat Gastrointestinal issues, including gastroparesis, gastroesophageal reflux (GERD), chemotherapy-related nausea and vomiting, and nausea and vomiting in some post-surgery patients
  2. Manufacturer ANI Pharmaceuticals Inc.
  3. Black Box Warnings Metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible and disfiguring disorder characterized by involuntary movements of the face, tongue, or extremities
  4. FDA Approval 1979
  5. Generic Form Metoclopramide
  6. Active Ingredient Metoclopramide
  7. Administration Route Oral
  8. Available Strength 5, 10 mg
  9. Dosage Form Tablet
  10. Drug Class Propulsives
  11. Is Available Generically True
  12. Is Proprietary True
  13. RxCUI 9230

Please seek the advice of a medical professional before making health care decisions.

Related Pages
Kristin Compton
Written By Kristin Compton Writer

Kristin Compton's background is in legal studies. She worked as a paralegal before joining Drugwatch as a writer and researcher. She was also a member of the National Association of Legal Assistants. A mother and longtime patient, she has firsthand experience of the harmful effects prescription drugs can have on women and their children. Some of her qualifications include:

  • Bachelor of Arts in Legal Studies | Pre-Law from University of West Florida
  • Past employment with The Health Law Firm and Kerrigan, Estess, Rankin, McLeod & Thompson LLC
  • Personal experience battling severe food allergies, asthma and high-risk pregnancies
Edited By
Medically Reviewed By
Venkatachala Mohan, MD
Dr. Venkatachala Mohan Internal Medicine, Gastroenterology

22 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Carpenter, W. T. and Koenig, J. (2007, November 28). The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities. Retrieved from
  2. Waln, O., and Jankovic, J. (2013, July 12). An Update on Tardive Dyskinesia: from Phenomenology to Treatment. Retrieved from
  3. U.S. Food and Drug Administration. (2017, April 11). FDA approves first drug to treat tardive dyskinesia. Retrieved from
  4. Hunter, C.B. et al. (n.d.) Medications Associated with the Onset of Tardive Dyskinesia. Retrieved from
  5. Connecticut Department of Developmental Services. (2007, August 20). DDS Medical Advisory #2000-2. Retrieved from
  6. Casteels-Van Daele, M. et al. (1970). Dystonic reactions in children caused by metoclopramide. Archives of Disease in Childhood, 45: 130–133. Retrieved from
  7. Institute for Safe Medication Practices. (2012, January 12). QuarterWatch (First Quarter 2011) Signals for dabigatran and metoclopramide. Retrieved from
  8. MedlinePlus. (2012, December 27). Tardive dyskinesia. Retrieved
  9. National Alliance on Mental Illness. (2013). Tardive dyskinesia. Retrieved from
  10. The American Psychiatric Association. (1992). Tardive dyskinesia: A task force report. American Psychiatric Association: Washington, D.C. Retrieved from
  11. Psychology Today. (2013). What is dopamine? Retrieved from
  12. Ehrenpreis, E.D. et al. (2013, June). The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Retrieved from
  13. Lee, A., and Kuo, B. (2011, January 26). Metoclopramide in the treatment of diabetic gastroparesis. Retrieved from
  14. Anaesth, B.J. (2012, September 25). Systemic metoclopramide to prevent postoperative nausea and vomiting: a meta-analysis without Fujii’s studies. Retrieved from
  15. Shapiro, E. (2012, August 7). Breastfeeding Pills’ Risky Results. Retrieved from
  16. U.S. Department of Health & Human Services. (n.d.). Letter re Reglan. Retrieved from
  17. U.S. Food and Drug Administration. (n.d.). Medication Guide. Retrieved from
  18. U.S. Food and Drug Administration. (n.d.). Reglan – metoclopramide tablet. Retrieved from
  19. DailyMed. NIH. (2017, August 29). Label: Reglan – metoclopramide hydrochloride tablet. Retrieved from
  20. MedlinePlus. NIH. (2016, December 1). Gastroparesis. Retrieved from
  21. MedlinePlus. NIH. (2016, January 28). Gastroesophageal reflux disease. Retrieved from
  22. Monson, K. & Schoenstadt, A. (2017, January 17). Important Details for Reglan How Does It Work? Retrieved from:
View All Sources
Who Am I Calling?

Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.

Drugwatch's sponsors support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our sponsors page.

(888) 645-1617